The role of pulse dexamethasone in acquired idiopathic thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 5, 2006, Pages 1148-1150

  Rojnuckarin, Ponlapat ^a,b   Watanaboonyongcharoen, P ^a   Akkawat, B ^a   Intragumtornchai, T ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; DIPYRIDAMOLE; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; STEROID; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIBODY PRODUCTION; ARTICLE; BINDING ASSAY; BLOOD SMEAR; BRAIN INFARCTION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; ECCHYMOSIS; ENZYME DEFICIENCY; FATIGUE; FEVER; HEMIPARESIS; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; MORTALITY; NEUROLOGIC DISEASE; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTE AGGLUTINATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADAM PROTEINS; ADULT; AGED; DEXAMETHASONE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 33645642803     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01879.x     Document Type: Article

References (17)

1. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
2. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
3. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Bohm M, Plaimauer B, Lammle B, Scheiflinger F. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-7.
4. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
5. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-8.
6. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-9.
7. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 2001; 98: 1765-72.
8. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grunfeld JP. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 2005; 106: 1932-7.
9. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403.
10. Toyoshige M, Zaitsu Y, Okafuji K, Inoue Y, Hiroshige Y, Matsumoto N, Kaku K, Kaneko T. Successful treatment of thrombotic thrombocytopenic purpura with high-dose corticosteroid. Am J Hematol 1992; 41: 69.
11. Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349: 831-6.
12. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-5.
13. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004; 104: 100-6.
14. Wada H, Kaneko T, Ohiwa M, Tanigawa M, Tamaki S, Minami N, Takahashi H, Deguchi K, Nakano T, Shirakawa S. Plasma cytokine levels in thrombotic thrombocytopenic purpura. Am J Hematol 1992; 40: 167-70.
15. Shariatmadar S, Nassiri M, Vincek V. Effect of plasma exchange on cytokines measured by multianalyte bead array in thrombotic thrombocytopenic purpura. Am J Hematol 2005; 79: 83-8.
16. Wandinger KP, Wessel K, Trillenberg P, Heindl N, Kirchner H. Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients. Acta Neurol Scand 1998; 97: 359-65.
17. George JN. How I treat patients with thrombotic thrombocytopenic purpura -hemolytic uremic syndrome. Blood 2000; 96: 1223-9.